EXACT Sciences Corporation (EXAS)vsIQVIA Holdings Inc (IQV)
EXAS
EXACT Sciences Corporation
$104.91
0.00%
HEALTHCARE · Cap: $20.03B
IQV
IQVIA Holdings Inc
$261.77
+1.74%
HEALTHCARE · Cap: $42.24B
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 423% more annual revenue ($16.98B vs $3.25B). IQV leads profitability with a 8.1% profit margin vs -6.4%. IQV earns a higher WallStSmart Score of 55/100 (C).
EXAS
Avoid32
out of 100
Grade: F
IQV
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EXAS.
Margin of Safety
+11.9%
Fair Value
$201.21
Current Price
$261.77
$60.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 23.1% year-over-year
Every $100 of equity generates 22 in profit
Growing faster than its price suggests
Areas to Watch
Trading at 8.3x book value
0.0% earnings growth
ROE of -8.7% — below average capital efficiency
Distress zone — elevated risk
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 0.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : EXAS
The strongest argument for EXAS centers on Revenue Growth. Revenue growth of 23.1% demonstrates continued momentum.
Bull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bear Case : EXAS
The primary concerns for EXAS are Price/Book, EPS Growth, Return on Equity.
Bear Case : IQV
The primary concerns for IQV are P/E Ratio, Piotroski F-Score, EPS Growth. Debt-to-equity of 2.63 is elevated, increasing financial risk.
Key Dynamics to Monitor
EXAS profiles as a growth stock while IQV is a value play — different risk/reward profiles.
EXAS carries more volatility with a beta of 1.44 — expect wider price swings.
EXAS is growing revenue faster at 23.1% — sustainability is the question.
IQV generates stronger free cash flow (360M), providing more financial flexibility.
Bottom Line
IQV scores higher overall (55/100 vs 32/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
EXACT Sciences Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Exact Sciences Corporation offers cancer screening and diagnostic test products in the United States and internationally. The company is headquartered in Madison, Wisconsin.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?